CD34 and familial dilated cardiomyopathy: Recently, this research group performed the REMEDIUM study, a phase II/III trial to investigate the effects of repetitive intramyocardial injection of CD34+ cells in patients with nonischemic DCM.56) Sixty patients (LVEF <40%, NYHA class III) were randomly allocated in a 1 : 1 ratio to receive either repetitive or single-dose CD34+ cell therapy.